Fig. 5: Prognostic value of ImmuneLENS lymphocyte fractions in 100KGP.
From: ImmuneLENS characterizes systemic immune dysregulation in aging and cancer
a, Five-year survival Kaplan–Meier plots for the entire pan-cancer 100KGP cohort, stratified into high and low groups based on the median circulating or infiltrating TCRA T cell fractions and IGH B cell fractions. b, Results from CoxPH models for 13,872 participants within the 100KGP pan-cancer cohort with complete clinical annotation. The models account for the effects of age, sex, genetically inferred ancestry, pretreatment chemotherapy and cancer stage. Left, pan-cancer HRs with 95% CIs. Right, a heatmap of HRs for different cancer histologies, including the I2 score from a meta-analysis using a random effects model across all histologies. Significance was calculated using Cochran’s Q test. Multiple hypothesis adjustments were performed using the Benjamini–Hochberg method, applied by row. Individual P values were calculated using a two-sided Wald test within the Cox model. *P < 0.05, **P < 0.01 and ***P < 0.001.
